Mineralocorticoid Receptor Antagonists: all 312 studies that test it

Page 3 of 4. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• A Study of the Beneficial Effects of Eplerenone on Central Serous ChorioretinopathyStatus unknownNCT02215330Phase 2/3
• Residual Renal Function Preservation in Peritoneal Dialysis PatientsStatus unknownNCT02190318Not applicable
• Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot StudyCompletedNCT02167464Not applicable
• Eplerenone For the Treatment of Chronic Central Serous ChorioretinopathyStatus unknownNCT02153125Phase 2
• Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in HumanCompletedNCT02129621Not applicable
• The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDiumCompletedNCT02118753Not applicable
• Spironolactone Against Anthracycline-induced CardiomyopathyCompletedNCT02053974Phase 4
• A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)WithdrawnNCT02047422Not applicable
• The Effect of Spironolactone on Pain in Older People With OsteoarthritisCompletedNCT02046668Phase 4
• Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With NormoalbuminuriaCompletedNCT02040441Phase 2/3
• Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by AntioxidantsStatus unknownNCT02027337Phase 4
• Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing HeartCompletedNCT01944384Phase 4
• Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular HypertrophyStatus unknownNCT01893788Phase 4
• Aldosterone Antagonism and Microvascular FunctionTerminatedNCT01887119Phase 4
• PHOspholamban RElated CArdiomyopathy STudy - InterventionCompletedNCT01857856Phase 3
• L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRDWithdrawnNCT01855334Phase 4
• ALdosterone Antagonist Chronic HEModialysis Interventional Survival TrialCompletedNCT01848639Phase 3
• Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin BTerminatedNCT01843309Phase 4
• Eplerenone and Extracellular Adenosine FormationCompletedNCT01837108Phase 4
• EPLErenone in CsA-Treated Recipients (EpleCsAT): SafetyStatus unknownNCT01834768Phase 2
• The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)Status unknownNCT01832558Not applicable
• A Prospective, Single-center, Open-label, Pilot Study to Compare the Effectiveness and Safety of Diuretics Add-On Strategy in Chronic Heart Failure Patients (DIOS 1)WithdrawnNCT01817803Not applicable
• Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side EffectsWithdrawnNCT01801228Phase 2
• Detection of Diffuse Scar in Patients With DiabetesWithdrawnNCT01794091Phase 4
• Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung DiseaseStatus unknownNCT01721655Phase 2/3
• Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast CancerTerminatedNCT01708798Phase 2/3
• Mineralocorticoid Receptor Antagonists in End Stage Renal DiseaseCompletedNCT01691053Phase 2
• Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis PatientsCompletedNCT01687699Phase 4
• Eplerenone in Hemodialysis TrialCompletedNCT01650012Not applicable
• Resistant Hypertension Optimal TreatmentStatus unknownNCT01643434Phase 4
• Comparison of Body Weight Change During Contraception With Belara and YasminStatus unknownNCT01608698Phase 4
• The Effects of Spironolactone on Calcineurin Inhibitor Induced NephrotoxicityCompletedNCT01602861Phase 4
• Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 DiabetesCompletedNCT01586442Phase 3
• Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous ChorioretinitisCompletedNCT01552044Phase 1/2
• The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on ProteinuriaCompletedNCT01541267Phase 4
• Spironolactone Plus Metformin in Polycystic Ovary SyndromeCompletedNCT01526616Not applicable
• Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.CompletedNCT01519401Not applicable
• Mineralocorticoid Receptor Antagonist and Kidney Allograft HistologyStatus unknownNCT01510795Phase 4
• Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial HypertensionStatus unknownNCT01468571Phase 4
• Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause WomenCompletedNCT01432028Not applicable
• Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal AtrophyCompletedNCT01407471Phase 2
• The Effect of Amiloride and Spironolactone in Patients With HypertensionCompletedNCT01388088Phase 4
• Effect of Eplerenone on Endothelial Function in Metabolic SyndromeCompletedNCT01319344Phase 3
• Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) PatientsWithdrawnNCT01302236Phase 4
• CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy RegressionWithdrawnNCT01275352Phase 4
• Recurrent Stroke Prevention Clinical Outcome StudyStatus unknownNCT01198496Phase 4
• The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular VariablesCompletedNCT01195805Not applicable
• Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver DiseaseCompletedNCT01147523Phase 2
• Effects of Spironolactone in DialysisStatus unknownNCT01128101Phase 4
• Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney FunctionTerminatedNCT01100203Phase 3
• Effect of Aldosterone Blockade on Arterial ComplianceCompletedNCT01089309Phase 4
• Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg TabletsCompletedNCT01083290Phase 1
• Aldosterone Blockade Early After Acute Myocardial InfarctionCompletedNCT01059136Phase 3
• Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant RecipientsSuspendedNCT01021943Phase 2
• Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential HypertensionTerminatedNCT00980031Not applicable
• Aldosterone in Diabetic NephropathyStatus unknownNCT00870402Phase 4
• Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed ConditionsCompletedNCT00865618Phase 1
• Importance of Aldosterone in the Pathogenesis of Hypertensive Heart DiseaseCompletedNCT00865501Phase 3
• Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal DialysisCompletedNCT00865449Phase 3
• Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting ConditionsCompletedNCT00865176Phase 1
• Hemodynamic Effects of Spironolactone in Patients With Heart FailureCompletedNCT00860340Not applicable
• The Effect of Amiloride and Spironolactone in Healthy PersonsCompletedNCT00857909Phase 1
• Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) WomenCompletedNCT00842140Not applicable
• A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese HypertensivesTerminatedNCT00825188Not applicable
• Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular FailureWithdrawnNCT00811486Not applicable
• Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)CompletedNCT00741663Phase 4
• Spironolactone Versus Amiloride as an Add on Agent in Resistant HypertensionWithdrawnNCT00709137Not applicable
• Eplerenone in Systemic Right VentricleCompletedNCT00703352Phase 4
• Spironolactone for Paroxysmal Atrial FibrillationStatus unknownNCT00689598Not applicable
• Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)CompletedNCT00664222Phase 4
• Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart FailureCompletedNCT00663195Phase 4
• Cycle Control and Safety of E2-DRSPCompletedNCT00653614Phase 2
• A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate HypertensionTerminatedNCT00649311Phase 2
• EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After CardioversionTerminatedNCT00647192Phase 2
• SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)CompletedNCT00604006Phase 3
• Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?Status unknownNCT00553722Phase 4
• Left Ventricular Hypertrophy and Spironolactone in End Stage Renal DiseaseWithdrawnNCT00548912Phase 4
• Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone SystemCompletedNCT00528385Not applicable
• Addition of Spironolactone in Patients With Resistant Arterial HypertensionStatus unknownNCT00524615Phase 4
• Aldosterone Blockade in Heart FailureCompletedNCT00523757Phase 3
• The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart FailureCompletedNCT00505336Not applicable
• Spironolactone for Reducing Proteinuria in Diabetic NephropathyCompletedNCT00498537Not applicable
• Inhibition of Aldosterone in Patients With Chronic Renal DiseaseCompletedNCT00430924Phase 4
• The Efficacy of Spironolactone in Patients With Resistant HypertensionTerminatedNCT00430794Phase 2
• Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF StudyCompletedNCT00403910Phase 3
• CMR to Assess Fibrosis in Cardiomyopathy Using EplerenoneCompletedNCT00401856Phase 4
• Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.CompletedNCT00356447Phase 3
• Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone TherapyCompletedNCT00335413Phase 4
• Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver CirrhosisStatus unknownNCT00332904Phase 4
• Spironolactone Safety in Dialysis PatientsWithdrawnNCT00328809Phase 4
• Spironolactone in Diabetic NephropathyCompletedNCT00317954Phase 4
• Eplerenone, ACE Inhibition and AlbuminuriaCompletedNCT00315016Phase 2
• Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart FailureTerminatedNCT00293150Phase 4
• Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?CompletedNCT00291720Phase 2
• Cardiovascular Protective Effect of Spironolactone in HemodialysisStatus unknownNCT00277693Phase 4
• Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides DiureticsCompletedNCT00276289Not applicable
• Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic AlcoholicsSuspendedNCT00226109Phase 4
• Treatment of Supine Hypertension in Autonomic FailureCompletedNCT00223717Phase 1
• Aldosterone and Vascular Disease in Diabetes MellitusCompletedNCT00214825Not applicable
• Novel Treatment for Diastolic Heart Failure in WomenCompletedNCT00206232Phase 4

← Mineralocorticoid Receptor Antagonists overview